MGC Diagnostics (MGCD) Reports Q2 EPS of $0.17 on Revenues of $10.41M

MGC Diagnostics (NASDAQ: MGCD) reported Q2 EPS of $0.17. Revenue for the quarter came in at $10.4 million, versus $0 reported last year.

Third Quarter 2017 Overview:

• Third quarter fiscal 2017 revenue increased by 6% to $10.4 million, compared to $9.9 million in the prior year period.
• Fiscal 2017 third quarter consolidated, domestic equipment, supplies and accessories revenues were $6.2 million, a 5% increase from $5.9 million in the fiscal 2016 third quarter.
• International equipment, supplies and accessories revenues increased 10% to $2.3 million for the quarter, compared to $2.1 million for the fiscal 2016 third quarter.
• Sales backlog increased 37% to $2.3 million at the end of the quarter, compared to $1.7 million at the end of the fiscal 2016 third quarter.
• Current and long-term deferred revenue at the end of the third quarter was $8.3 million, an increase of 7.8%, from $7.7 million at the end of last year\'s third quarter.
• Recurring revenue, consisting of services and supplies, for the 2017 third quarter increased 1.4% to $3.9 million representing 38% of total revenue, compared to $3.9 million, or 39% of total revenue in the prior year period.
• Operating income for the fiscal 2017 third quarter was $751,000, compared to operating income of $794,000 in the prior year period.
• Net income increased 193% to $760,000, or $0.17 per diluted share for the fiscal 2017 third quarter, compared to net income of $260,000, or $0.06 per diluted share, in the fiscal 2016 third quarter, due in large part to a $657,000 foreign currency pre-tax gain as the Euro strengthened against the dollar.

For earnings history and earnings-related data on MGC Diagnostics (MGCD) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Reading (RDI) Tops Q2 EPS by 4c
• SanDisk upgraded at JPMorgan after investor day; shares climb